1. Menendez CE, Rivlin RS 1973 Thyrotoxic crisis and myxoedema coma. Med Clin North Amer 57:1463-1470.
2. Lahey FH 1928 The crisis of exophthalmic goitre. N Engl J 199:255.
3. Nelson NC, Becker WF 1969 Thyroid crisis: diagnosis and treatment. Ann Surg 170:263-273.
4. Kobayashi C, Sasaki H, Kosuge K, Miyakita Y, Hayakawa M, Suzuki A, Abe E, Suzuki K, Aizawa Y.2005 Severe starvation hypoglycemia and congestive heart failure induced by thyroid crisis, with accidentally induced severe liver dysfunction and disseminated intravascular coagulation. Intern Med. 44:234-239.
5. Mackin JF, Canary JJ, Pittman CS 1978 Thyroid storm and its management. N Eng J Med 291:1396-1398.
6, Dillman WH 1997 Thyroid storm. Curr Ther Endocrinol Metab 6:81-85
7. McDermott MT, Kidd GS, Dodson LE, Hofeldt FD 1983 Radioiodine-induced thyroid storm. Am J Med 75:353-359.
8. Rosenberg I 1970 thyroid storm. N Engl J Med 283:1052-1053.
9. Brooks MH, Waldstein SS 1980 Free thyroxine concentrations in thyroid storm. An Int Med 93,694-697.
10.Kidess AI, Caplan RH,Reynertson RH, Wickus G 1991 Recurrence of 131-I induced thyroid storm after discontinuing glucocorticoid therapy. Wis Med J 90:463-465,1991.
11. Kadmon PM, Noto RB, Boney CM, Goodwin G, Gruppuso PA 2001 Thyroid storm in a child following radioactive iodine (RAI) therapy: a consequence of RAI versus withdrawal of antithyroid medication. J Clin Endocrinol Metab. 86:1865-1867.
12. Birkhauser M, Busset R, Burer Th, Burger A 1977 Diagnosis of hyperthyroidism when serum thyroxine alone is raised. Lancet 2:53-56.
13. Thomas DJ, Hardy J, Sarwar R, Banner NR, Mumani S, Lemon K, Hillson RM 2006 Thyroid storm treated with intravenous methimazole in patients with gastrointestinal dysfunction. Br J Hosp Med. 67: 492-493.
14. Nabil N, Miner DJ, Amatruda JM 1982 Methimazole: An alternative route of administration. J Clin Endocrinol Metab 54:180-181.
15. Felber J-P, Reddy WJ, Selenkow HA, Thorn GW 1959 Adrenocortical reponse of the 48-hour ACTH test in myxedema and hyperthyroidism. J Clin Endocrinol Metab 19:895.
16. Abrams JJ, Sandler J 1977 Propranolol for thyroid storm. N Engl J Med 296:1120.
17. Hellmann T,Kelly KL, Mason WD 1977 Propranolol for thyroid storm. N Engl J Med 297:671.
18. Burger AG, Philippe J 1992 Thyroid emergencies. Bailliere’s Clin Endocrinol Metab 6:77-93.
19. Witztum Jl, Jacobs LS, Schonfeld G 1978 Thyroid hormone and thyrotropin levels in patients placed on colestipol hydrochloride. J Clin Endocrinol Metab 46:838-840.
20. Bartalena L, Pinchera A, Marcocci C 2000 Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev 21: 168-199.
21. Wiersinga WM, Bartalena L 2002 Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid 12: 855-860.
22. Bartley GB 1994 The epidemiological characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 92: 477-588.
23. Forbes G, Gorman CA, Brennan MD, Gehring DG, Ilstrup DM, Earnest F 1986 Ophthalmopathy of Graves’ disease: computerized volume measurement of the orbital fat and muscle. Am J Neuroradiol 7: 651-656.
24. Gamblin GT, Harper DG, Galentine P, Buck DR, Chernow B, Eil C 1983 Prevalence of increased intraocular pressure in Graves’ disease: evidence of frequent subclinical ophthalmopathy. N Engl J Med 308: 420-424.
25. Krassas GE, Wiersinga WM 2005 Thyroid eye disease: current concepts and the EUGOGO perspective. Thyroid International no. 4: 1-21.
26. Marcocci C, Bartalena L, Bogazzi F, Panicucci M, Pinchera A 1989 Studies on the occurrence of ophthalmopathy in Graves’ disease. Acta Endocrinol (Copenh) 120: 473-478.
27. Perros P, Crombie AL, Matthews JNS, Kendall-Taylor P 1993 Age and gender influence the severity of thyroid associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clin Endocrinol (Oxf) 38: 367-372.
28. Perros P, Crombie AL, Kendall-Taylor P 1995 Natural history of thyroid-associated ophthalmopathy. Clin Endocrinol (Oxf) 42: 45-50.
29. Kendall-Taylor P, Perros P 1998 Clinical presentation of thyroid associated orbitopathy. Thyroid 8: 427-428.
30. Prummel MF, Bakker A, Wiersinga WM, Baldeschi L, Mourits MP, Kendall-Taylor P, Perros P, Neoh C, Dickinson AJ, Lazarus JH, Lane CM, Heufelder AE, Kahaly GJ, Pitz S, Orgiazzi J, Hullo A, Pinchera A, Marcocci C, Sartini MS, Rocchi R, Nardi M, Krassas GE, Halkias A 2003 Multi-center study on the characteristics and treatment strategies of patients with Graves’ orbitopathy: the first European Group on Graves’ Orbitopathy experience. Eur J Endocrinol 148: 491-495.
31. Bartalena L, Bogazzi F, Tanda ML, Manetti L, Dell’Unto E, Martino E 1995 Cigarette smoking and the thyroid. Eur J Endocrinol 133: 507.512.
32. Bartalena L, Martino E, Marcocci C, Bogazzi F, Panicucci M, Velluzzi F, Loviselli A, Pinchera A 1989 More on smoking habits and Graves’ ophthalmopathy. J Endocrinol Invest 12: 733-737.
33. Holm IA, Manson JAE, Michels KB, Alexander EK, Willett WC, Utiger RD 2005 Smoking and other lifestyle factors and the risk of Graves’ hyperthyroidism. Arch Intern Med 165: 1606-1611.
34. Prummel MF, Wiersinga WM 1993 Smoking and risk of Graves’ disease. JAMA 269: 479-482.
35. Krassas GE, Segni M, Wiersinga WM 2005 Childhood Graves’ ophthalmopathy: results of a European questionnaire study. Eur J Endocrinol 153: 515-521.
36. Bartalena L, Marcocci C, Pinchera A 2002 Graves’ ophthalmopathy: a preventable disease? Eur J Endocrinol 146: 457-461.
37. Szucs-Farkas Z, Todt J, Kollar J, Galuska L, Barman KD, Boda J, Leovey A, Varga J, Ujhelyi B, Szabo J, Berta A, Nagy EV 2005 Volume changes in intra- and extraorbital compartments in patients with Graves’ ophthalmopathy: effect of smoking. Thyroid 15: 146-151.
38. Cawood TJ, Moriarty P, O’Farrelly C, O’Shea D 2007 Smoking and thyroid-associated ophthalmopathy: a novel explanation of the bilogical link. J Clin Endocrinol Metab 92: 59-64.
39. Bahn RS 2003 Pathophysiology of Graves’ ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab 88: 1939-1946.
40. Prabhakar BS, Bahn RS, Smith TJ 2003 Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocr Rev 24: 802-835.
41. Burch HB, Wartofsky l 1993 Graves’ ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 14: 747-793.
42. Heufelder AE 1995 Pathogenesis of Graves’ ophthalmopathy: recent controversies and progress. Eur J Endocrinol 132: 532-541.
43. Ajjan AR, Weetman AP 2004 New understanding of the role of cytokines in the pathogenesis of Graves’ ophthalmopathy. J Endocrinol Invest 27: 237-245.
44. Feldon SE, Park DJJ, O’Loughlin CW, Nguyen VT, Landskroner-Eiger S, Chang D, Thatcher TH, Phipps RP 2005 Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves’ ophthalmopathy. Invest Ophthalmol Vis Sci 46: 3913-3921.
45. Wakelkamp IM, Bakker O, Baldeschi L, Wiersinga WM, Prummel MF. 2003 TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves’ ophthalmopathy patients. Clin Endocrinol (Oxf) 58: 280-287.
46. Smith TJ, Hoa N 2004 Immunoglobulins from patients with Graves’ disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab 89: 5076-5080.
47. Kumar S, Leontovich, Coenen MJ, Bahn RS 2005 Gene expression profiling of orbital adipose tissue from patients with Graves’ ophthalmopathy: a potential role for secreted frizzled-related protein-1 in orbital adipogenesis.
48. Lantz M, Vondrichova T, Parikh H, Frenander C, Ridderstrale M, Asman P, Aberg M, Groop L, Hallengren B 2005 Overexpression of immediate early genes in active Graves’ ophthalmopathy. J Clin Endocrinol Metab 90: 4784-4791.
49. Valyasevi RW, Harteneck DA, Dutton CM, Bahn RS 2002 Stimulation of adipogenesis, proxisome proliferator-activated receptor- (PPAR-), and thyrotropin receptor by PPAR- agonist in human orbital preadipocyte fibroblasts. J Clin Endocrinol Metab 87: 2352-2358.
50. Starkey K, Heufelder AE, Baker G, Joba W, Evans M, Davies M, Ludgate M 2003 PPAR in thyroid eye disease: contraindication to thiazolidenedione use? J Clin Endocrinol Metab 88: 55-59.
51. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Sellari Franceschini S, Serio M, Ferrannini E 2006 Interferon--inducible -chemokine CXCL10 involvement in Graves’ ophthalmopathy: modulation by peroxisome proliferator-activated receptor- agonists. J Clin Endocrinol Metab 91: 614-620.
52. Bartalena L 2005 Graves’ ophthalmopathy: search for shared autoantigen(s) continues. J Endocrinol Invest 28: 396-397.
53. Bahn RS 2004 TSH receptor expression in orbital tissue and its role in the pathogenesis of Graves’ ophthalmopathy. J Endocrinol Invest 27: 216-220.
54. Agretti P, De Marco G, De Servi M, Marcocci C, Vitti P, Pinchera A, Tonacchera M 2005 Evidence for protein and mRNA expression in fibroblasts from patients with thyroid-associated ophthalmopathy (TAO) after adipocytic differentiation. Eur J Endocrinol 152: 777-784.
55. Agretti P, Chiovato L, De Marco G, Marcocci C, Mazzi B, Sellari-Franceschini S, Vitti P, Pinchera A, Tonacchera M 2002 Real-time PCR provides evidence for thyrotropin receptor mRNA expression in orbital as well as in extraorbital tissues. Eur J Endocrinol 147: 733-739.
56. Garrity JA, Bahn RS 2006 Pathogenesis of Graves’ ophthalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol 142: 147-153.
57. Ludgate M, Baker G 2004 Inducing Graves’ ophthalmopathy. J Endocrinol Invest 27: 211-215.
58. Gerding MN, van der Meer JW, Boenink M, Bakker O, Wiersinga WM, Prummel MF 2000 Association of thyrotrophin receptor antibodies with clinical features of Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 52: 267-271.
59. Mikozami T, Salvi M, Wall JR 2004 Eye muscle antibodies in Graves’ ophthalmopathy: pathogenic or secondary epiphenomenon? J Endocrinol Invest 27: 221-229.
60. Marinò M, Chiovato L, Lisi S, Altea MA, Marcocci C, Pinchera A 2004 Role of thyroglobulin in the pathogenesis of Graves’ ophthalmopathy: the hypothesis of Kriss revisited. J Endocrinol Invest 27: 230-236.
61. Kahaly GJ, Bang H, Berg W, Dittmar M 2005 Alpha-fodrin as a putative autoantigen in Graves’ ophthalmopathy. Clin Exp Immunol 140: 166-172.
62. Wiersinga WM, Prummel MF 2001 Pathogenesis of Graves’ ophthalmopathy – Current understanding. J Clin Endocrinol Metab 86: 501-503.
63. Vaidya B, Kendall-Taylor P, Pearce SHS 2002 The genetics of autoimmune thyroid disease. J Clin Endocrinol Metab 87: 5385-5397.
64. Kretowski A, Wawrusiewicz N, Mironczuk K, Musliwiec J, Kretowska M, Kinalska I 2003 Intercellular adhesion molecule 1 gene polymorphisms in Graves’ disease. J Clin Endocrinol Metab 88: 4945-4949.
65. Bednarczuk T, Hiromatsu Y, Fukutani T, Jazdzewski K, Miskiewicz P, Osikowska M, Nauman J 2003 Association of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) gene polymorphism and non-genetic factors with Graves’ ophthalmopathy in European and Japanese populations. Eur J Endocrinol 148: 13-18.
66. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R. 1989 Amelioration of eye changes of Graves’ ophthalmopathy by achieving euthyroidism. Acta Endocrinol (Copenh) 121: 185-189.
67. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R. 1990 Effect of abnormal thyroid function on the severity of Graves’ ophthalmopathy. Arch Intern Med 150: 1098-1101.
68. Karlsson AF, Westermark K, Dahlberg PA, Jansson R, Enksson P 1989 Ophthalmopathy and thyroid stimulation. Lancet 2: 691.
69. Eckstein AK, Plicht M, Lax H, Neuhauser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG 2006 Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91: 3464-3470.
70. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren J-G, Blomgren H, Taube A & the Thyroid Study Group. 1992 Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. N Engl J Med 326: 1733-1738.
71. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A 1998 Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med 338: 73-78.
72. Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A 1989 Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 321: 1349-1352.
73. Marcocci C, Bruno-Bossio G, Manetti L, Tanda ML, Miccoli P, Iacconi P, Bartolomei MP, Nardi M, Pinchera A, Bartalena L 1999 The course of Graves’ ophthalmopathy is not influenced by near-total thyroidectomy. Clin Endocrinol (Oxf) 51: 503-508.
74. Werner SC 1977 Modification of the classification of the eye changes of Graves’ disease: recommendations of the ad hoc committee of the American Thyroid Association. J Clin Endocrinol Metab 44: 203-206.
75. The European Group on Graves’ Orbitopathy (EUGOGO): Wiersinga WM, Perros P, Kahaly GJ, Mourits MP, Baldeschi L, Boboridis K, Boschi A, Dickinson AJ, Kendall-Taylor P, Krassas GE, Lane CM, Lazarus JH, Marcocci C, Marinò M, Nardi M, Neoh C, Orgiazzi J, Pinchera A, Pitz S, Prummel MF, Sartini MS, Stahl M, von Arx G 2006 Clinical assessment of patients with Graves’ orbitopathy: the European Group on Graves’ Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 155: 387-389.
76. Dickinson AJ, Perros P 2001 Controversies in the clinical evaluation of thyroid-associated orbitopathy: use of a detailed protocl with comparative photographs for objective assessment. Clin Endocrinol (Oxf) 55: 283-303.
77. Wiersinga WM, Prummel MF, Terwee CB 2004 Effects of Graves’ ophthalmopathy on quality of life. J Endocrinol Invest 27: 259-264.
78. Gerding MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF, Wiersinga WM 1997 Quality of life in patients with Graves’ ophthalmopathy is markedly decreased: measurement by the Medical Outcomes Study instrument. Thyroid 7: 885-889.
79. Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM 1998 Development of a disease-sepcific quality of life questionnaire for patients with Graves’ ophthalmopathy. Br J Ophthalmol 82: 773-779.
80. Terwee CB, Wakelkamp I, Tan S, Dekker F, Prummel MF, Wiersinga WM 2002 Long-term effects of Graves’ ophthalmopathy on health-related quality of life. Eur J Endocrinol 146: 751-757.
81. Kahaly GJ, Petrak F, Hardt J, Pitz S, Egle UT 2005 Psychosocial morbidity of Graves’ orbitopathy. Clin Endocrinol (Oxf) 63: 395-402.
82. Terwee CB, Dekker FW, Mourits MP, Gerding MN, Baldeschi L, Kalmann R, Prummel MF, Wiersinga WM 2001 Interpretation and validity of changes in scores in the GO-QOL after different treatments. Clin Endocrinol (Oxf) 54: 391-398.
83. Wiersinga WM, Prummel MF 2002 Graves’ ophthalmopathy: a rational approach to treatment. Trends Endocrinol Metab 13: 280-287.
84. Mourits M, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R 1989 Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol 73: 639-644.
85. Pinchera A, Wiersinga WM, Glinoer D, Kendall-Taylor P, Koornneef L, Marcocci C, Schleusener H, Romaldini J, Niepominiscze F, Solomon D, Garrity J, Gorman CA 1992 Classification of eye changes of Graves’ disease. Thyroid 2: 235-236.
86. Kahaly GJ 2004 Recent developments in Graves’ ophthalmopathy imaging. J Endocrinol Invest 27: 254-258.
87. The European Group of Graves’ Orbitopathy: Perros P, Baldeschi L, Boboridis K, Dickinson AJ, Hullo A, Kahaly GJ, Kendall-Taylor P, Krassas GE, Lane CM, Lazarus JH, Marcocci C, Marinò M, Mourits MP, Nardi M, Orgiazzi J, Pinchera A, Pitz S, Prummel MF, Wiersinga WM 2006 A questionnaire survey on the management of Graves’ orbitopathy in Europe. Eur J Endocrinol 155: 207-211.
88. Bartalena L, Marcocci C, Pinchera A. 1997 Treating severe Graves’ ophthalmopathy. Bailliere’s Clin Endocrinol Metab 11: 521-536.
89. Uddin JM, Davies PD 2002 Treatment of upper lid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection. Ophthalmology 118: 410-413.
90. Pfeilschifter J, Ziegler R 1996 Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol (Oxf) 45: 477-481.
91. Bartalena L, Marcocci C, Tanda ML, Pinchera A 2002 Management of thyroid eye disease. Eur J Nucl Med 29 (Suppl 2): S458-S465.
92. Marcocci C, Marinò M, Rocchi R, Monconi F, Morabito E, Pinchera A 2004 Novel aspects of immunosuppressive and radiotherapy management of Graves’ ophthalmopathy. J Endocrinol Invest 27: 272-280.
93. Bartalena L, Marcocci C, Tanda ML, Piantanida E, Lai A, Marinò M, Pinchera A 2005 An update on medical management of Graves’ ophthalmopathy. J Endocrinol Invest 28: 469-478.
94. Krassas GE, Heufelder AE 2001 Immunosuppressive therapy in patients with thyroid eye disease: an overview of current concepts. Eur J Endocrinol 144: 311-318.
95. Ebner R, Devoto MH, Weil D, Bordaberry M, Mir C, Martinez H, Bonelli L, Niepomniszcze H 2004 Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol 88: 1380-1386.
96. Bartalena L 2005 Glucocorticoids for Graves’ ophthalmopathy: how and when. J Clin Endocrinol Metab 90: 5497-5499.
97. Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell’Unto E, Rocchi R, Barbesino G, Mazzi B, Bartolomei MP, Lepri P, Cartei F, Nardi M, Pinchera A 2001 Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves’ ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 86: 3562-3567.
98. Marinò M, Morabito E, Brunetto MR, Bartalena L, Pinchera A, Marcocci C 2004 Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves’ ophthalmopathy. Thyroid 14: 403-406.
99. Kahaly GJ, Pitz S, Hommel G, Dittmar M 2005 Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab 90: 5234-5240.
100. Hart Franzco RH, Kendall-Taylor P, Crombie A, Perros P 2005 Eraly response to intravenous glucocorticoids for severe thyroid-associated ophthalmopathy predicts treatment outcome. J Ocular Pharmacol Ther 21: 328-336.
101. Bartalena L, Marcocci C, Pinchera A 2004 Orbital radiotherapy for Graves’ ophthalmopathy. J Clin Endocrinol Metab 89: 13-14.
102. Bartalena L, Marcocci C, Tanda ML, Rocchi R, Mazzi B, Barbesino G, Pinchera A 2002 Orbital radiotherapy for Graves’ ophthalmopathy. Thyroid 12: 245-250.
103. Kahaly GJ, Rosler H-P, Pitz S, Hommel G 2000 Low- versus high-dose radiotherapy for Graves’ ophthalmopathy: a randomized, single blind trial. J Clin Endocrinol Metab 85: 102-108.
104. Bartalena L, Marcocci C, Gorman CA, Wiersinga WM, Pinchera A 2003 Orbital radiotherapy for Graves’ ophthalmopathy: useful or useless? Safe or dangerous. J Endocrinol Invest 26: 5-16.
105. Prummel MF, Mourits MP, Blank L, Berghout A, Koornneef L, Wiersinga WM 1993 Rnadomised, double-blind trial of prednisone versus radiotherapy in Graves’ ophthalmopathy. Lancet 342: 949-954.
106. Mourits MP, van Kempen-Harteveld ML, Garcia MB, Koppeschaar HPF, Tick L, Terwee CB 2000 Radiotherapy for Graves’ orbitopathy: randomised, placebo-controlled study. Lancet 355: 1505-1509.
107. Gorman CA, Garrity JA, Fatourechi V, Bahn RS, Petersen IA, Stafford SL, Earle JD, Forbes GS, Kline RW, Bergstrahl EJ, Offord KP, Rademacher DM, Stanley NM, Bartley GB 2001 A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves’ ophthalmopathy. Ophthalmology 108: 1523-1534.
108. Prummel MF, Terwee CB, Gerding MN, Baldeschi L, Mourits MP, Blank L, Dekker FW, Wiersinga WM 2004 A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves’ ophthalmopathy. J Clin Endocrinol Metab 89: 15-20.
109. Marcocci C, Bartalena L, Rocchi R, Marinò M, Menconi F, Morabito E, Mazzi B, Mazzeo S, Sartini MS, Nardi M, Cartei F, Cionini L, Pinchbera A 2003 Long-term safety of orbital radiotherapy for Graves’ ophthalmopathy. J Clin Endocrinol Metab 88: 3561-3566.
110. Wakelkamp IMMJ, Tan H, Saeed P, Sckingemann RO, Verbraak FD, Blank LECM, Prummel MF, Wiersinga WM 2004 Orbital irradiation for Graves’ ophthalmopathy. Is it safe? A long-term follow-up study. Ophthalmology 111: 1557-1562.
111. Bartalena L, Marcocci C, Chiovato L, Laddaga M, Lepri G, Andreani D, Cavallacci G, Baschieri L, Pinchera A 1983 Orbital cobalt irradiation combined with systemic corticosteroids for Graves’ ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab 56: 1139-1144.
112. Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Lepri A, Pinchera A 1991 Orbital radiotherapy combined with high-dose systemic glucocorticoids for Graves’ ophthalmopathy is more effective than orbital radiotherapy alone: results of a prospective study. J Endocrinol Invest 14: 853-860.
113. Pasquali D, Vassallo P, Esposito D, Bonavolontà G, Bellastella A, Sinisi AA 2000 Somatostatin receptor gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves’ ophthalmopathy. J Mol Endocrinol 25: 63-71.
114. Pasquali D, Notaro A, Bonavolontà G, Vassallo P, Bellastella A, Sinisi AA 2002 Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves’ disease. J Clin Endocrinol Metab 87: 5125-5129.
115. Krassas GE 2004 Somatostatin analogs: a new tool for the management of Graves’ ophthalmopathy. J Endocrinol Invest 27: 281-287.
116. Dickinson AJ, Vaidya B, Miller M, Coulthard A, Perros P, Baister E, Andrews CD, Hesse L, Heverhagen JT, Heufelder AE, Kendall-Taylor P 2004 Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 89: 5910-5915.
117. Wemeau JL, Caron P, Beckers A, Rohmer V, Orgiazzi J, Borson-Chazot F, Nocuadie M, Perimenis P, Bisot-Locard S, Bourdeix I, Dejager S 2005 Octreotide (long-acting release formulation) treatment in patients with Graves’ orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab 90: 841-848.
118. Chang T-C, Liao S-L 2006 Slow-release lanreotide in Graves’ ophthalmopathy: a double-blind randomized, placebo-controlled clinical trial. J Endocrinol Invest 29: 413-422.
119. Stan MN, Garrity JA, Bradley EA, Woog JJ, Bahn MM, Brennan MD, Bryant SC, Achenbach SJ, Bahn RS 2006 Randomized, placebo-controlled, double-blind trial of long-acting release octreotide for treatment of Graves’ ophthalmopathy. J Clin Endocrinol Metab 91: 4817-4824.
120. Bartalena L, Marcocci C, Pinchera A 2004 Somatostatin analogs for Graves’ ophthalmopathy: do they bounce off like a rubber bullet? J Clin Endocrinol Metab 89: 5908-5909.
121. Tanda ML, Bartalena L 2006 Currently available somatostatin analogs are not good for Graves’ orbitopathy. J Endocrinol Invest 29: 389-390.
122. Kahaly G, Schrenzemeir, Krause U, Schweikert B, Meuer S, Muller W 1986 Ciclosporin and prednisone v. Prednisone in treatment of Graves’ ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest 16: 415-422.
123. Prummel MF, Mourits MP, Berghout A, Krenning EP, van der Gaag R, Koornneef L, Wiersinga AM 1989 Prednisone and cyclosporine in the treatment of severe Graves’ ophthalmopathy. N Engl J Med 321: 1353-1359.
124. Wakelkamp IMMJ, Baldeschi L, Saeed P, Mourits MP, Prummel MF, Wiersinga WM 2005 Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves’ ophthalmopathy? A randomized controlled trial. Clin Endocrinol (Oxf) 63: 323-328.
125. Fatourechi V, Garrity JA, Bartley GB, Bergstrahl EJ, DeSanto LW, Gorman CA 1994 Graves’ ophthalmopathy. Results of transantral orbital decompression performed primarily for cosmetic indications. Ophthalmology 101: 938-942.
126. Kallmann R, Mourits MP, vand der Pol JP, Koornneef L 1997 Coronal approach for rehabilitative orbital decompression in Graves’ ophthalmopathy. Br. J Ophthalmol 81: 41-45.
127. Garrity JA, Fatourechi V, Bartley GB, Bergstrahl EJ, DeSanto LW, Gorman CA 1994 Graves’ ophthalmopathy. Results of transantral orbital decompression in 428 patients with severe Graves’ ophthalmopathy. Am J Ophthalmol 116: 533-547.
128. Bartalena L, Wiersinga WM, Pinchera A 2004 Graves’ ophthalmopathy: state of the art and perspectives. J Endocrinol Invest 27: 295-301.
129. Marcocci C, Bartalena L, Pinchera A 1998 Ablastive or non-ablative therapy for Graves’ hyperthyroidism in patients with ophthalmopathy? J Endocrinol Invest 21: 468-471.
130. Weetman AP, Harrison BJ 1998 Ablastive or non-ablative therapy for Graves’ hyperthyroidism in patients with ophthalmopathy? J Endocrinol Invest 21: 472-475.
131. DeGroot LJ, Benjasuratwong Y 1996 Evaluation of thyroid ablative therapy for ophthalmopathy of Graves’ disease. Orbit 15: 187-196.
132. Moleti M, Mattina F, Salomone I, Violi MA, Nucera C, Baldari S, Lo Schiavo MG, Regalbuto C, Trimarchi F, Vermiglio F 2003 Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of Graves’ ophthalmopathy. Thyroid 13: 653-658.
133. Menconi F, Marinò M, Pinchera A, Rocchi R, Mazzi B, Nardi M, Bartalena L, Marcocci C 2007 Effects of total thyroid ablation vs near-total thyroidectomy alone on mild to moderate Graves’ orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab 92: 000-000.
134. Bartalena L, Tanda ML 2006 Immunotherapy for Graves’ orbitopathy: easy enthusiasm, but let’s keep trying. J Endocrinol Invest 29: 1012-1016.
135. Hasselbach HC 2003 B cell depletion with rituximab – a targeted therapy for Graves’ disease and autoimmune thyroiditis. Immunol Lett 88: 85-86-
136. El Fassi D, Nielsen CH, Hasselbach HC, Hegedus L 2006 The rationale for B lymphocyte depletion in Graves’ disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur J Endocrinol 154: 623-632.
137. El Fassi D, Nielsen CH, Hasselbach HC, Hegedus 2006 Treatment-resistant severe, active Graves’ ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid 16: 709-710.
138. Salvi M, Vannucchi G, Campi I, Rossi S, Bonara P, Sbrozzi F, Guastella C, Avignone S, Pirola G, Ratiglia R, Beck-Peccoz P 2006 Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol 154: 511-517.
139. Salvi M, Vannucchi G, Campi I, Currò N, Dazzi D, Simonetta S, Bonara P, Rossi S, Sina C, Guastella C, Ratiglia R, Beck-Peccoz P 2007 Treatment of Graves’ disease and associated ophthalmopathy with anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 156: 33-40.
140. Paridaens D, van den Bosch WA, van der Loos TL, Krenning EP, van Hagen PM 2005 The effect of etanercept on Graves’ ophthalmopathy: a pilot study. Eye 19: 1286-1289.
141. Bartalena L, Tanda ML, Piantanida E, Lai A 2003 Oxidative stress and Graves’ ophthalmopathy: in vitro studies and therapeutic implications. BioFactors 19: 155-163.
142. Balazs C, Kiss A, Vamos I, Molnar R, Farid NR 1997 Beneficial effect of pentoxifylline on thyroid associated ophthalmopathy (TAO): a pilot study. J Clin Endocrinol Metab 1999-2002.
143. Bouzas EA, Karadimas P, Mastorakos G, Koutras DA 2000 Antioxidants agents in the treatment of Graves’ ophthalmopathy. Am J Ophthalmol 129: 618-622.
144. Fatourechi V, Bartley GB, Eghbali-Fatourechi GZ, Powell CC, Ahmed DD, Garrity JA 2003 Graves’ dermopathy and acropachy are markers of severe Graves’ ophthalmopathy. Thyroid 13: 1141-1144.
145. Bartley GB, Fatourechi V, Kadrmas EF, Ilstrup DM, Garrity JA, Gorman CA 1996 Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol 121: 284-290.
146. Schwartz KM, Fatourechi V, Ahmed DDF, Pond GR 2002 Dermopathy of Graves’ disease (pretibial myxedema): long-term outcome. J Clin Endocrinol Metab 87:438-446.
147. Tong DW, Ho KK 1998 Pretibial myxedema presenting as a scar infiltrate. Australas J Dermatol 39:255-257.
148. Misner CS, Ramsay EW, Houck He, Kauffman CL 1998 Graves’disease presenting as a localized myxedema in a thigh donor graft site. J Am Ac Dermatol 39:864-869,1998.
149. Cohen JB, Balzer B, Wapnir I, McDougall IR 2004 Elephantiasic pretibial myxedema. Thyroid 14: 237-238.
150. Vatourechi V 2005 Pretibial myxedema: pathophysiology and treatment options. Am J Clin Dermatol 6: 295-309.
151. Smith TJ, Bahn RS, Gorman CA 1989 Connective tissue, glycosaminoglycans, and diseases of the thyroid. Endocr Rev 10: 366-391.
152. Bull RH, Coburn PR, Mortimer PS 1993 Pretibial myxoedema: a manifestation of lymphoedema? Lancet 341:403.
153. Heufelder AE, Bahn RS, Scriba PC 1995 Analysis of T-cell receptor variable region gene usage in patients with thyroid-related pretibial dermopathy. J Invest Dermatol 105:372-378.
154. Bahn RS 1995 The fibroblast is the target cell in connective tissue manifestations of Graves' disease. Int Arch Allergy Immunol 106:213-218.
155. Shishiba Y, Imai Y, Odajima R, Ozawa Y, Shimizu T 1992 Immunoglobulin G of patients with circumscribed pretibial myxedema of Graves' disease stimulates proteoglycan synthesis in human skin fibroblasts in culture. Acta Endocrinol(Copenh) 127:44-51.
156. Hanke CW, Bergfeld WF, Guirguis MN, Lewis LJ 1983 Hyaluronic acid synthesis in fibroblasts of pretibial myxedema. Cleve Clin Q 50:129-133.
157. Heufelder AE, Dutton CM, Sarkar G, Donovan KA, Bahn RS 1993 Detection of TSH receptor RNA in cultured fibroblasts from patients with Graves’ ophthalmopathy and pretibial dermopathy. Thyroid 3: 297-300.
158. Rapoport B, Alsabeh R, Aftergood D, McLachlan SM 2000 Elephantiasic pretibial myxedema: insight into a hypothesis regarding the pathogenesis of the extrathyroidal manifestations of Graves’ disease. Thyroid 10: 685-692.
159. Wu SL, Chang TC, Chang TJ 1996 Cloning and sequencing of complete thyrotropin receptor transcripts in pretibial fibroblast culture cells. J Endocrinol Invest 19:365-370.
160. Stadlmayer W, Spitzweg C, Bichlmair AM, Heufelder AE 1997 TSH receptor transcripts and TSH receptor-like immunoreactivity in orbital and pretibial fibroblasts of patients with Graves' ophthalmopathty and pretibial myxedema. Thyroid 7:3-12.
161. Daumerie C, Ludgate M, Costagliola S, Many MC 2002 Evidence for thyrotropin receptor immunoreactivity in pretibial connective tissue from patients with thyroid-associated dermopathy. Eur J Endocrinol. 146:35-38.
162. Metcalfe RA, Davies R, Weetman AP 1993 Analysis of fibroblast-stimulating activity in IgG from patients with Graves’ dermopathy. Thyroid 3: 207-212.
163. Fatourechi V, Pajouhi M, Fransway AF 1994 Dermopathy of Graves’ disease (pretibial myxedema): review of 150 cases. Medicine (baltimore) 73: 1-7.
164. Kriss JP 1987 Pathogenesis and treatment of pretibial myxedema. Endocrinol Metab Clin North Amer 16:409-415.
165. Ohtsuka Y, Yamamoto K, Goto Y, Mizuta T, Ozaki I, Setoguchi Y, Kohda H, Sakai T 1995 Localized myxedema, associated with increased serum hyaluronic acid, and response to steroid pulse therapy. Intern Med 34:424-429,1995
166. Wendy S. Susser, Amanda G. Heermans, M. Shane Chapman, Richard D. Baughma 2002 Elephantiasic pretibial myxedema: a novel treatment for an uncommon disorder. J Am Acad Dermatol 46:723-726.
167. Felton J, Derrick EK, Price ML 2003 Successful combined surgical and octreotide treatment of severe pretibial myxoedema reviewed after 9 years. Br J Dermatol 148: 825-826.
168. Rotman-Pikielny P, Brucker-Davis F, Turner ML, Sarlis NJ, Skarulis MC 2003 Lack of effect of long-term octreotide therapy in severe thyroid-associated dermopathy. Thyroid 13: 465-470.
169. Jolles S, Hughes J 2006 Use of IGIV in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis, and pretibial myxedema. Int Immunopharmacol 6: 579-591.
170. Fatourechi V, Ahmed DDF, Schwartz KM 2002 Thyroid Acropachy: report of 40 patients treated at a single institution in a 26-year period. J Clin Endocrinol Metab 2002 87: 5435-5441
171. Anderson CK, Miller OF 2003 Triad of exophthalmos, pretibial myxedema, and acropachy in a patient with Graves' disease. J Am Acad Dermatol 48:970-2.
172. Kahaly GJ, Dillmann WH 2005 Thyroid hormone action in the heart. Endocr Rev 26: 704-728.
173. Kahaly GJ, Wagner S, Nieswandt J, Mohr-Kahaly S, Rayan TJ 1999 Stress echocardiography in hyperthyroidism. J Clin Endocrinol Metab 84:2308-2313.
174. Osman F, Franklyn JA, Holder RL, Sheppard MC, Gammage MD 2007 Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy. J Am Coll Cardiol 49: 71-81.
175. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P 1998 Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med 338: 712-718.
176. Osman F, Gammage MD, Franklyn JA 2002 Hyperthyroidism and cardiovascular morbidity and mortality. Thyroid 12: 483-488.
177. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA 2001 Prediction of all cause and cardiovascular mortality in elderly people from one low serum thyrotropin result : a 10-year cohort study. Lancet 358: 861-865.
178. Channick BJ, Adlin EV, Marks AD, Denenberg BS, McDonough MT, Chakko CS, Spann JF 1981 Hyperthyroidism and mitral-valve prolapse. N Engl J Med 305:497-502.
179. Kahaly GJ, Nieswandt J, Mohr-Kahaly S 1998 Cardiac risk of hyperthyroidism in the elderly. Thyroid 8:1165-1169.
180. Agner T, Almdal T, Thorsteinsson B, Agner E 1984 A reevaluation of atrial fibrillation in thyrotoxicosis. Dan Med Bull 31: 157-159.
181. Nakazawa HK, Sakurai K, Hamada N, Momotani N, Ito K 1982 Management of atrial fibrillation in the post-thyrotoxic state. Am J Med 72:903-906.
182. Rohmer V, Hocq R, Galland F, Getin F, Tadei A, Jallet P, Bigorgne JC 1984 Hyperthyreoidie fruste révélée par un trouble du rythme auriculaire. Press Med 13:145-149.
183. Sawin LT, Geller A, Wolf PhA, Belanger A, Baker E 1994 Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. New Engl J Med 331:1249-1253.
184. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman CA, Cooper DS, Weissman NJ 2004 ,Subclinical thyroid disease: scientific review and guidelines for diagnosis and management JAMA 291:228-238.
185. Trivelle C, Doucet J, Chassagne P, Landrin I, Kadri N, Menare JF, Bercoff E 1996 Differences in the signs and symptoms of hyperthyroidism in older and younger patients. J Am Geriatr Soc 44: 50-53.
186. Kahaly GJ, Kampmann C, Mohr-Kahaly S 2002 Cardiovascular hemodynamics and exercise tolerance in thyroid disease. Thyroid 12:473-8.
187. Boccalandro C, Boccalandro F, Orlander P, Wei CF 2003 Severe reversible dilated cardiomyopathy and hyperthyroidism: case report and review of the literature. Endocr Pract 9:140-6.
188. Featherstone HJ, Stewart DK 1983 Angina in thyrotoxicosis: thyroid related coronary artery spasm. Arch Intern Med 143: 554-558.
189. Moliterno D, Debold CR, Robertson RM 1992 Coronary vasospasm – relation to the hyperthyroid state. Am J Med Sci 304: 38-42
190. Resenkov L, Falicov R 1977 Thyrotoxicosis and lactate producing angina pectoris with normal coronary arteries. Br Heart J 39:1051-1055.
191. Kotler N, Kyriakos M, Bouchard J, Warbasse JR 1973 Myocardial infarction associated with thyrotoxicosis. Arch Intern Med 132:723-728.
192. Ladenson PW 1993 Thyrotoxicosis and the heart: something old and something new. J Clin Endocrinol Metab 77:332-333.
193. Biondi B, Fazio S, Carella C, Amato G, Littadini A, Lupoli G, Saca L, Bellastella A, Lombardi G. 1993 Cardiac effects of long-term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 77:334-338.
194. Shapiro LE, Sievart R, Ong L, Ocamo E, Chance R, Lee M, Nanna M, Ferrick K, Surks M 1997 Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine. J Clin Endocrinol Metab 82:2592-2595.
195. Nakazawa H, Lythall DA, Noh J, Ishikawa N, Sugino K, Ito K, Hardman SM 2000 Is there a place for late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation. Eur Heart J 12:327-333.